title: Retrospective analysis of mantle cell lymphoma: experience of the "Gruppo Italiano per lo Studio dei Linfomi" (GISL).
abstract: OBJECTIVE
  Mantle cell lymphoma is a recently recognized histologic entity with specific biological and clinical features. Clinically, the reported unfavorable outcome of these patients has focused attention on this category of non-Hodgkin's lymphoma (NHL).
  
  
  METHODS
  The slide specimens of 69 NHL patients, originally classified as Working Formulation (WF) group B and E, were reviewed. The clinical features at presentation, response to therapy, response duration and survival were analyzed in cases reclassified as MCL. The correlation between clinical and histologic characteristics and the final outcome was evaluated.
  
  
  RESULTS
  Out of 69 cases, 34 specimens were reclassified as MCL; in 6 patients, previously classified as WF group B, the nodular pattern was confirmed; in 2 instances the blastoid form was recognized. After a median follow-up of 35.7 months, the entire series displayed a median overall survival of 41.2 months; a significantly longer survival was associated with the nodular histologic pattern, IPI score < 2, response achievement, and a higher Hb level. The vast majority of patients received anthracycline-containing combination chemotherapy. Complete remission rate was 38.8% and overall response rate was 67.6%; response achievement was significantly influenced only by Hb level. Median response duration was 23.3 months.
  
  
  CONCLUSIONS
  The present study confirms the unfavorable clinical course of MCL and the possible need for an alternative therapeutic strategy for this NHL category. Therefore, the correct identification of MCL at diagnosis appears of relevance.
authors.affiliation: Dipartimento di Emato-Oncologia, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy. sp00404@relay.it.net
authors.forename: V
authors.initials: V
authors.lastname: Callea
authors.forename: V
authors.initials: V
authors.lastname: Clò
authors.forename: F
authors.initials: F
authors.lastname: Morabito
authors.forename: L
authors.initials: L
authors.lastname: Baldini
authors.forename: C
authors.initials: C
authors.lastname: Stelitano
authors.forename: F
authors.initials: F
authors.lastname: Narni
authors.forename: P
authors.initials: P
authors.lastname: Avanzini
authors.forename: M
authors.initials: M
authors.lastname: Brugiatelli
authors.forename: V
authors.initials: V
authors.lastname: Silingardi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008228:Lymphoma, Non-Hodgkin / Q000145:classification / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000903:Antibiotics, Antineoplastic; D006454:Hemoglobins